ArticleBMC ophthalmology2025
Analysis of risk factors associated with meibomian gland orifice obstruction severity in glaucoma patients: a clinical investigation.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeTo investigate the synergistic effects of duration of glaucoma and number of medications on meibomian gland orifice obstruction severity in glaucoma patients, aiming to optimize therapeutic strategies for ocular surface protection.
methodsThis retrospective study analyzed 120 glaucoma patients with concurrent MGD. Meibomian gland orifice obstruction was scored using standardized criteria. The relationship between obstruction scores and clinical factors was evaluated using Spearman correlation and generalized linear modeling.
resultsSignificant correlations were found between MG orifice obstruction score and duration of glaucoma (r = 0.309, P < 0.001), number of medications (r = 0.340, P < 0.001), number of preserved eye drop products (r = 0.300, P < 0.001) and duration of medication (r = 0.398, P < 0.001). Generalized linear modeling revealed significant main effects of duration of glaucoma and number of medications (P = 0.012 and P = 0.005), with a significant interaction (P = 0.020). After 3 years of glaucoma, any medication regimen significantly increased obstruction scores compared to no treatment (all P < 0.05). Triple or quadruple therapy showed significantly higher obstruction scores versus no medication (P = 0.002 and P = 0.008).
conclusionDuration of glaucoma and number of medications synergistically worsen MG orifice obstruction, with a critical threshold after one year of disease. These findings suggest the importance of reducing medication burden in long-term glaucoma patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.